J. Goldman & CO LP Black Diamond Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
97Shares Held
41.5MCall Options Held
68.7KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$45.2 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.55MShares$23.4 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.7 Million1.03% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$9.22 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $153M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...